Relationship between leukocyte count and patient risk for excessive blood loss after cardiac surgery

Critical Care Medicine

Volumn 25, Issue 8, 1997, Pages 1338-1346

  Despotis, George J ^a   Levine, Vladimir ^a   Goodnough, Lawrence T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood component transfusion; Cardiac surgery; Cell counters; Coagulation monitoring; Complete blood cell count; Hematocrit; Hemoglobin; Platelet count; Red blood cell count; White blood cell count

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD COMPONENT THERAPY; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURGICAL RISK;

ADULT; AGED; BAYES THEOREM; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0030850055     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199708000-00021     Document Type: Article

References (84)

1. Kirklin JK: The postperfusion syndrome: Inflammation and the damaging effects of cardiopulmonary bypass. In: Cardiopulmonary Bypass: Current Concepts and Controversies. Tinker JH (Ed). Philadelphia, WB Saunders, 1989, pp 131-146
2. Woodman RC, Harker LA: Bleeding complications associated with cardiopulmonary bypass. Review. Blood 1990; 76:1680-1697
3. Khuri SF, Wolfe JA, Josa M, et al: Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104:94-107
4. Despotis GJ, Santoro SA, Spitznagel E, et al: Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107:271-279
5. Tuman KJ, Spiess BD, McCarthy RJ, et al: Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989; 69:69-75
6. Mongan PD, Hosking MP: The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46
7. Dorman BH, Spinale FG, Bailey MK, et al: Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: Thromboelastography versus coagulation screen. Anesth Analg 1993; 76:694-700
8. Gravlee GP, Arora S, Lavender SW, et al: Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58:216-221
9. Burns ER, Billett HH, Frater RW, et al: The preoperative bleeding time as a predictor of postoperative hemorrhage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986; 92:310-312
10. Ramsey G, Arvan DA, Stewart S, et al: Do preoperative laboratory tests predict blood transfusion needs in cardiac operations? J Thorac Cardiovasc Surg 1983; 85:564-569
11. Despotis GJ, Levine V, Filos K, et al: Evaluation of a new, point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85: 1311-1323
12. Wang JS, Lin CY, Hung WT, et al: Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992; 53:435-439
13. Klindworth JT, MacVeigh I, Ereth MH: The platelet activated clotting test (PACT) predicts platelet dysfunction associated with cardiopulmonary bypass (CBP). Abstr. Anesth Analg 1996; 82:99
14. Despotis GJ, Ikonomakou S, Levine V, et al: Effects of platelets, white blood cells and antiplatelet agent c7E3 (Reopro™) on a new test of PAF procoagulant activity of whole blood. Thromb Res 1997; 86:205-219
15. Chu SH, Hu RH, Lee YC, et al: Changes of white blood cells, immunosuppressive acidic protein, and interleukin-2 receptor after open heart surgery. Thorac Cardiovasc Surg 1995; 43:94-98
16. Jensen RH, Storgaard M, Vedelsdal R, et al: Impaired neutrophil chemotaxis after cardiac surgery. Scand J Thorac Cardiovasc Surg 1995; 29:115-118
17. Khan FA, Kamal RS, Mithani CH, et al: Effect of general anaesthesia and surgery on neutrophil function. Anaesthesia 1995; 50:769-775
18. Rinder CS, Bohnert J, Rinder HM, et al: Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991; 75:388-393
19. Rinder HM, Bonan JL, Rinder CS, et al: Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78:1730-1737
20. Despotis GJ, Joist JH, Hogue CW, et al: The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1995; 110:46-54
21. Chernow B, Salem M, Stacey J: Blood conservation - A critical care imperative. Crit Care Med 1991; 19:313-314
22. Chernow B: Blood conservation in critical care - The evidence accumulates. Crit Care Med 1993; 21:481-482
23. Peruzzi WT, Parker MA, Lichtenthal PR, et al: A clinical evaluation of a blood conservation device in medical intensive care unit patients. Crit Care Med 1993; 21:501-506
24. Silver MJ, Jubran H, Stein S, et al: Evaluation of a new blood-conserving arterial line system for patients in intensive care units. Crit Care Med 1993; 21:507-511
25. Shapiro BA, Mahutte CK, Cane RD, et al: Clinical performance of a blood gas monitor: A prospective, multicenter trial. Crit Care Med 1993; 21:487-494
26. Zimmerman JL, Dellinger RP: Initial evaluation of a new intra-arterial blood gas system in humans. Crit Care Med 1993; 21:495-500
27. Goodnough LT: Blood conservation and blood transfusion practices: Flip sides of the same coin. Ann Thorac Surg 1993; 56:3-4
28. Despotis GJ, Filos KS, Zoys TN, et al: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82:13-21
29. Harker LA: Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314:1446-1448
30. Rinder CS, Mathew JP, Rinder HM, et al: Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991; 75:563-570
31. Beurling-Harbury C, Galvan CA: Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978; 52:13-23
32. George JN, Shattil SJ: The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324:27-39
33. Hardy JF, Perrault J, Tremblay N, et al: The stratification of cardiac surgical procedures according to use of blood products: A retrospective analysis of 1480 cases. Can J Anaesth 1991; 38:511-517
34. Despotis GJ, Joist JH, Hogue CW, et al: More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76:902-908
35. Verstraete M: Clinical application of inhibitors of fibrinolysis. Review. Drugs 1985; 29:236-261
36. Horrow JC: Desmopressin and antifibrinolytics. Review. Int Anesthesiol Clin 1990; 28:230-236
37. Czer LS: Mediastinal bleeding after cardiac surgery: Etiologies, diagnostic considerations, and blood conservation methods. Review. J Cardiothorac Anesth 1989; 3:760-775
38. Kalter RD, Saul CM, Wetstein L, et al: Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979; 77:427-435
39. Shainoff JR, Estafanous FG, Yared JP, et al: Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 108: 437-445
40. Holloway DS, Summaria L, Sandesara J, et al: Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59:62-67
41. Sloand EM, Alyono D, Klein HG, et al: 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46:199-207
42. Harker LA, Malpass TW, Branson HE, et al: Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56:824-834
43. Greilich PE, Carr ME Jr, Carr SL, et al: Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995; 80:459-465
44. Ray MJ, Hawson GA, Just SJ, et al: Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994; 57:981-986
45. Lynch JM, Lotner GZ, Betz SJ, et al: The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol 1979; 123:1219-1226
46. Snyder F: Biochemistry of platelet-activating factor: A unique class of biologically active phospholipids. Proc Soc Exp Biol Med 1989; 190:125-135
47. Hanahan DJ, Buxton D, Halvorsen O, et al: Platelet-activating factor: A unique lipid chemical mediator. Adv Prostaglandin Thromboxane Leukot Res 1985; 15:707-709
48. Macconi D, Foppolo M, Paris S, et al: PAF mediates neutrophil adhesion to. thrombin or TNF-stimulated endothelial cells under shear stress. Am J Physiol 1995; 269:C42-C47
49. Raff GW, Spillert CR, Wilson DJ, et al: Procoagulant property of platelet activating factor (PAF). Agents Actions 1993; 39:C106
50. Rotllan E, Escolar G, Ordinas A, et al: Effect of PAF (platelet-activating factor) on hemostasis. Studies on endothelial cells and platelets [in Spanish]. Sangre (Barc) 1993; 38:115-119
51. Perussia B, Jankiewicz J, Trinchieri G: Binding of platelets to human monocytes: A source of artifacts in the study of the specificity of antileukocyte antibodies. J Immunol Methods 1982; 50:269-276
52. Ferrer-Lopez P, Renesto P, Schattner M, et al: Activation of human platelets by C5a-stimulated neutrophils: A role for cathepsin G. Am J Physiol 1990; 258:C1100-C1107
53. Nguyën P, Petitfrere E, Potron G: Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. Thromb Res 1995; 78:33-42
54. Gaboury J, Woodman RC, Granger DN, et al: Nitric oxide prevents leukocyte adherence: Role of superoxide. Am J Physiol 1993; 265:H862-H867
55. Altieri DC, Mannucci PM, Capitanio AM: Binding of fibrinogen to human monocytes. J Clin Invest 1986; 78: 968-976
56. Drake TA, Ruf W, Morrissey JH, et al: Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109:389-395
57. Altieri DC, Edgington TS: The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988; 263:7007-7015
58. Altieri DC, Morrissey JH, Edgington TS: Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci U S A 1988; 85:7462-7466
59. Lojek A, Cerny J, Pillich J, et al: Human neutrophil mobilization during open heart surgery. Physiol Res 1992; 41:431-436
60. Molad I, Berliner S, Arber N, et al: Increased leukocyte adhesiveness/aggregation and tissue leukostasis following surgical trauma. Int Surg 1993; 78:20-24
61. Kirklin JK, Westaby S, Blackstone EH, et al: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-857
62. Kirklin JK, Blackstone EH, Kirklin JW: Cardiopulmonary bypass: Studies on its damaging effects. Blood Purif 1987; 5:168-178
63. Rinder CS, Bonan JL, Rinder HM, et al: Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79:1201-1205
64. Chang R, Wong GY: Prognostic significance of marked leukocytosis in hospitalized patients. J Gen Intern Med 1991; 6:199-203
65. Yu M, Levy MM, Smith P, et al: Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: A prospective, randomized, controlled study. Crit Care Med 1993; 21:830-838
66. Wachtfogel YT, Kucich U, Greenplate J, et al: Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69:324-330
67. Riegel W, Spillner G, Schlosser V, et al: Plasma levels of main granulocyte components during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1988; 95:1014-1019
68. Rashid MA, William-Olsson G: Are leukocytosis and lipid peroxidation involved in ischemic or reperfusion injury in cardiac surgery? Thorac Cardiovasc Surg 1991; 39:193-195
69. Jansen NJ, van Oeveren W, van den Broek L, et al: Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102:515-525
70. Jansen NJ, van Oeveren W, van Vliet M, et al: The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 1991; 5: 211-217
71. Redmond JM, Gillinov AM, Stuart RS, et al: Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993; 56:474-479
72. Bando K, Pillai R, Cameron DE, et al: Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99:873-877
73. Johnson D, Thomson D, Mycyk T, et al: Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiorespiratory status. Chest 1995; 107: 1253-1259
74. Morioka K, Muraoka R, Chiba Y, et al: Leukocyte and platelet depletion with a blood cell separator: Effects on lung injury after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 111:45-54
75. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Review. Arzneimittelforschung 1983; 33:479-494
76. Murase M, Usui A, Tomita Y, et al: Nafamostat mesylate reduces blood loss during open heart surgery. Circulation 1993; 88:432-436
77. Andreasson S, Gothberg S, Berggren H, et al: Hemofiltration modifies complement activation after extracorporeal circulation in infants. Ann Thorac Surg 1993; 56:1515-1517
78. Millar AB, Armstrong L, van der Linden J, et al: Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993; 56:1499-1502
79. Journois D, Pouard P, Greeley WJ, et al: Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components. Anesthesiology 1994; 81:1181-1189
80. Dietrich W, Dilthey G, Spannagl M, et al: Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995; 83:679-689
81. van Oeveren W, Jansen NJ, Bidstrup BP, et al: Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44:640-645
82. Wachtfogel YT, Kucich U, Hack CE, et al: Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106:1-10
83. Royston D: High-dose aprotinin therapy: A review of the first five years' experience. Review. J Cardiothorac Vasc Anesth 1992; 6:76-100
84. Bidstrup BP, Harrison J, Royston D, et al: Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55:971-976